2-(2-(diphenylamino)ethyl)isoindolin-1,3-dione | 86922-38-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(2-(diphenylamino)ethyl)isoindolin-1,3-dione
• 英文别名: 2-[2-(N-phenylanilino)ethyl]isoindole-1,3-dione
• CAS: 86922-38-5
• 化学式: C₂₂H₁₈N₂O₂
• 分子量: 342.397
• InChiKey: GNAQPMSEFOVYQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.12
• 重原子数：
  26.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  40.62
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  2-(2-(diphenylamino)ethyl)isoindolin-1,3-dione 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 36.0h， 以14%的产率得到N,N-二苯基乙烯二胺
  参考文献：
  名称：

  可溶性环氧水解酶和5-脂氧合酶双重抑制剂的设计，合成及构效关系研究

  摘要：

  花生四烯酸级联的多种酶的抑制导致协同的抗炎作用。5-脂氧合酶（5-LOX）和可溶性环氧化物水解酶（sEH）药效团的合并导致发现了双重5-LOX / sEH抑制剂，随后针对靶标和代谢稳定性进行了优化。优化的铅结构在人多形核白细胞中显示出细胞活性，口服生物利用度以及体内靶标结合，并且在小鼠单侧输尿管阻塞引起的肾脏损伤模型中显示出深远的抗炎和抗纤维化功效。这些结果为研究5-LOX / sEH双重抑制剂在其他炎症和纤维化相关疾病模型中的治疗潜力铺平了道路。

  DOI：

  10.1021/acs.jmedchem.0c00561
• 作为产物：
  描述：

  二苯胺 在 sodium tetrahydroborate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 8.0h， 生成 2-(2-(diphenylamino)ethyl)isoindolin-1,3-dione
  参考文献：
  名称：

  可溶性环氧水解酶和5-脂氧合酶双重抑制剂的设计，合成及构效关系研究

  摘要：

  花生四烯酸级联的多种酶的抑制导致协同的抗炎作用。5-脂氧合酶（5-LOX）和可溶性环氧化物水解酶（sEH）药效团的合并导致发现了双重5-LOX / sEH抑制剂，随后针对靶标和代谢稳定性进行了优化。优化的铅结构在人多形核白细胞中显示出细胞活性，口服生物利用度以及体内靶标结合，并且在小鼠单侧输尿管阻塞引起的肾脏损伤模型中显示出深远的抗炎和抗纤维化功效。这些结果为研究5-LOX / sEH双重抑制剂在其他炎症和纤维化相关疾病模型中的治疗潜力铺平了道路。

  DOI：

  10.1021/acs.jmedchem.0c00561

文献信息

• [EN] DUAL INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND 5-LIPOXYGENASE<br/>[FR] INHIBITEURS DOUBLES D'ÉPOXYDE HYDROLASE SOLUBLE ET DE 5-LIPOXYGÉNASE
  申请人：JOHANN WOLFGANG GOETHE UNIV FRANKFURT AM MAIN

  公开号：WO2021214048A1

  公开（公告）日：2021-10-28

  The invention pertains to a novel structure (I) that provides an activity as a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and 5-lipoxygenase (5-LOX). The invention pertains to multiple derivatives of the new class of dual inhibitors, their application in medicine, pharmaceutical compositions comprising them as well as to methods for synthesizing the new compounds.

  该发明涉及一种新型结构（I），作为可溶性环氧酰水解酶（sEH）和5-脂氧化酶（5-LOX）的双重抑制剂提供活性。该发明涉及新型双重抑制剂类的多个衍生物，它们在医学中的应用，包含它们的制药组合物，以及合成新化合物的方法。
• Antagonists of slow-reacting substance of anaphylaxis. 1. Pyrido[2,1-b]quinazolinecarboxylic acid derivatives
  作者：Jefferson W. Tilley、Paul Levitan、Ann F. Welton、Herman J. Crowley

  DOI：10.1021/jm00365a016

  日期：1983.11

  Members of a series of basic amide and ester derivatives of 2-substituted pyrido[2,1-b]quinazoline-8-carboxylic acids were prepared and evaluated for their ability to prevent slow-reacting substance of anaphylaxis (SRS-A) induced contractions of guinea pig ilea. The results indicate that the presence of a branched-chain alkyl group in the 2-position and a sterically demanding substituted aminoethyl carboxylate or carboxamide in the 8-position give optimal in vitro activity. The phenylpiperazine 25 was further found to block SRS-A-related symptomatology after intravenous administration in two animal models.
• Reversal Agent and Linker Variants of Reversed Chloroquines: Activities against <i>Plasmodium falciparum</i>
  作者：Simeon Andrews、Steven J. Burgess、Deborah Skaalrud、Jane Xu Kelly、David H. Peyton

  DOI：10.1021/jm900972u

  日期：2010.1.28

  We have shown that "reversed chloroquine molecules" constructed from chloroquine-like and resistance "reversal-agent"-like cores can be powerful drugs against malaria (J. Med. Chem. 2006, 49, 5623-5625). Several reversed chloroquines are now presented that probe parameters governing the activities against chloroquine-resistant and chloroquine-sensitive malaria strains. The design is tolerant to linker and reversal agent changes, but it piperazinyl group adjacent to the quinoline, at least for the group Of Compounds studied here, may be detrimental.
• Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718
  作者：Arie Van der Bent、Armand G. S. Blommaert、Caroline T. M. Melman、Adriaan P. IJzerman、Ineke Van Wijngaarden、Willem Soudijn

  DOI：10.1021/jm00084a009

  日期：1992.3

  A series of novel nonpeptide cholecystokinin-A (CCK-A) antagonists have been synthesized. Designed on the basis of the structural homology between lorglumide and L-364,718, as investigated with molecular modeling, these compounds constitute a link between the N-acylglutamic acid and 3-amino-5-phenyl-1,4-benzodiazepin-2-one derived antagonists. The prepared compounds were tested in vitro as antagonists of the binding of [H-3]-(+/-)-L-364,718 and [H-3]-CCK-8(S) to rat pancreas and guinea pig brain membranes, respectively. All compounds proved to be selective for the (peripheral) CCK-A receptor, the most potent analogue, 6, having a K(i) value of 90 nM. The structure-activity profile of the series of hybrid compounds relates closest to that of the N-acylglutamic acid derived antagonists.
• TILLEY, J. W.;LEVITAN, P.;WELTON, A. F.;CROWLEY, H. J., J. MED. CHEM., 1983, 26, N 11, 1638-1642
  作者：TILLEY, J. W.、LEVITAN, P.、WELTON, A. F.、CROWLEY, H. J.

  DOI：——

  日期：——